CRH Medical Corp. | StockChase
83
CRH Medical Corp. (CRH-T)

Last Price Recorded: $3.2300 on 2018-01-16

ON STOCKCHASE SINCE Jul 2009

biotechnology/pharmaceutical
83
CRH Medical Corp. (CRH-T)

Last Price Recorded: $3.2300 on 2018-01-16

ON STOCKCHASE SINCE Jul 2009

biotechnology/pharmaceutical

CRH Medical Corp.


Signal Opinion Expert
COMMENT
CRH Medical Corp.(CRH-T) 

December 15, 2017

Had this in his Growth portfolio, and it just didn’t work out. A situation where a company gets oversold. It will probably have a good January bounce because of all the tax loss selling that has probably occurred over the last couple of weeks or months. He is having a hard time with this. Would like to support it on valuation, but in terms of execution it has issues with payor codes changing, and the revenue growth is largely beyond the company's control. They haven't handled the past year very well. He would put this in the "OK" category, but with 10,000 public companies to choose from, it is well low on his list.

biotechnology/pharmaceutical

Had this in his Growth portfolio, and it just didn’t work out. A situation where a company gets oversold. It will probably have a good January bounce because of all the tax loss selling that has probably occurred over the last couple of weeks or months. He is having a hard time with this. Would like to support it on valuation, but in terms of execution it has issues with payor codes changing, and the revenue growth is largely beyond the company's control. They haven't handled the past year very well. He would put this in the "OK" category, but with 10,000 public companies to choose from, it is well low on his list.

biotechnology/pharmaceutical
Peter Hodson

CEO & Head of Research, 5i Research Inc....

PricePrice
$3.010
Owned Owned
Unknown

WATCH
CRH Medical Corp.(CRH-T) 

December 4, 2017

He was one of the first buyers.  He sold half his position when it was disproportionately high and then the rest on the way down.  The market has lost confidence in management, who also sold a lot of shares in the $7 range.  If it broke through $3.30 on heavy volume he would take a good look but there are better options until then.

biotechnology/pharmaceutical

He was one of the first buyers.  He sold half his position when it was disproportionately high and then the rest on the way down.  The market has lost confidence in management, who also sold a lot of shares in the $7 range.  If it broke through $3.30 on heavy volume he would take a good look but there are better options until then.

biotechnology/pharmaceutical
Jason Del Vicario

Portfolio Manager, HollisWealth...

PricePrice
$2.610
Owned Owned
No

COMMENT
CRH Medical Corp.(CRH-T) 

November 24, 2017

Has been badly beaten up. In 2014, revenues were about $11 million, and are now looking at about $100 million. BV is around $.85, so it is still trading at around 3X BV. The important thing is that insiders have been selling like crazy. When this happens, that is not a good sign. Not a contrarian stock to his way of thinking.

biotechnology/pharmaceutical

Has been badly beaten up. In 2014, revenues were about $11 million, and are now looking at about $100 million. BV is around $.85, so it is still trading at around 3X BV. The important thing is that insiders have been selling like crazy. When this happens, that is not a good sign. Not a contrarian stock to his way of thinking.

biotechnology/pharmaceutical
Benj Gallander

President, Contra the Heard Inv...

PricePrice
$2.520
Owned Owned
No

DON'T BUY
CRH Medical Corp.(CRH-T) 

November 14, 2017

Thinks management got caught off guard with the Medicare/Medicaid changes. Listening to the calls, he didn’t have a lot of confidence. Their business model is a bit broken now. With the share price and valuation so low, they are not getting as much bang for their buck now. Heading into the tax loss season, this is probably going to be one of the big targets. He would sit on the sidelines, at least until the new year.

biotechnology/pharmaceutical

Thinks management got caught off guard with the Medicare/Medicaid changes. Listening to the calls, he didn’t have a lot of confidence. Their business model is a bit broken now. With the share price and valuation so low, they are not getting as much bang for their buck now. Heading into the tax loss season, this is probably going to be one of the big targets. He would sit on the sidelines, at least until the new year.

biotechnology/pharmaceutical
Ryan Modesto

Managing Partner, 5i Research...

PricePrice
$1.920
Owned Owned
Unknown

COMMENT
CRH Medical Corp.(CRH-T) 

November 13, 2017

They are in the US mainly and partner with anesthesiologists, for gut surgeries.  There is a whole system in the US as to who can treat whom and what they will pay.  These guys have been hit because of lack of organic growth and the concern is whether the reduced amount the Medicaid is willing to pay will impact margins going forward.  He thinks it is overdone.

biotechnology/pharmaceutical

They are in the US mainly and partner with anesthesiologists, for gut surgeries.  There is a whole system in the US as to who can treat whom and what they will pay.  These guys have been hit because of lack of organic growth and the concern is whether the reduced amount the Medicaid is willing to pay will impact margins going forward.  He thinks it is overdone.

biotechnology/pharmaceutical
Brendan Caldwell

President, Caldwell Securities...

PricePrice
$2.080
Owned Owned
Unknown

PAST TOP PICK
CRH Medical Corp.(CRH-T) 

November 8, 2017

(A Top Pick Nov 16/16. Down 71%.) A few things happened. Have had 2 reimbursement cuts. Hasn’t affecting earnings yet, but it will. It’s been an acquisition story and they’ve been buying anaesthesiology clinics using their stock as currency. That becomes difficult now because of the low stock price.

biotechnology/pharmaceutical

(A Top Pick Nov 16/16. Down 71%.) A few things happened. Have had 2 reimbursement cuts. Hasn’t affecting earnings yet, but it will. It’s been an acquisition story and they’ve been buying anaesthesiology clinics using their stock as currency. That becomes difficult now because of the low stock price.

biotechnology/pharmaceutical
Bruce Campbell (2)

President & Portfolio Manager, Stone Castle Investm...

PricePrice
$2.180
Owned Owned
No

DON'T BUY
CRH Medical Corp.(CRH-T) 

October 19, 2017

It has not done anything at all for him and is on a short leash.  It is drifting back now.  He would be concerned about tax loss selling soon.  There is value there but don’t start a position.

biotechnology/pharmaceutical

It has not done anything at all for him and is on a short leash.  It is drifting back now.  He would be concerned about tax loss selling soon.  There is value there but don’t start a position.

biotechnology/pharmaceutical
Peter Hodson

CEO & Head of Research, 5i Research Inc....

PricePrice
$2.940
Owned Owned
Yes

TOP PICK
CRH Medical Corp.(CRH-T) 

October 4, 2017

Has been looking at this for over 2 years, and met management repeatedly. Was aware of the Short attack circulating this summer, which had some pretty interesting important points to make. When a share price goes from $12 to around $3, his view is that it was fully priced in and there was a big overreaction by the street. They are exclusively based in the US, and have a medical product that is used by gastroenterologists in the clinics, kind of a Trojan horse for them because they have the clinics that are using the medical product, so have a relationship with them. With a number of the clinics, they have effectively bought 50% of the clinic, which allows them to provide the anaesthesia services on behalf of the doctors who work there. A pristine balance sheet. (Analysts’ price target is $5.)

biotechnology/pharmaceutical

Has been looking at this for over 2 years, and met management repeatedly. Was aware of the Short attack circulating this summer, which had some pretty interesting important points to make. When a share price goes from $12 to around $3, his view is that it was fully priced in and there was a big overreaction by the street. They are exclusively based in the US, and have a medical product that is used by gastroenterologists in the clinics, kind of a Trojan horse for them because they have the clinics that are using the medical product, so have a relationship with them. With a number of the clinics, they have effectively bought 50% of the clinic, which allows them to provide the anaesthesia services on behalf of the doctors who work there. A pristine balance sheet. (Analysts’ price target is $5.)

biotechnology/pharmaceutical
Jerome Hass

Portfolio Manager, Lightwater Partners...

PricePrice
$3.260
Owned Owned
Yes

SELL
CRH Medical Corp.(CRH-T) 

September 28, 2017

He exited this story.  He was a big bull.  It came back for stock specific stories.  Multiple compression resulted from short reports. 

biotechnology/pharmaceutical

He exited this story.  He was a big bull.  It came back for stock specific stories.  Multiple compression resulted from short reports. 

biotechnology/pharmaceutical
Peter Imhof

Vice President & Portfolio Manager, AGF Investments Inc...

PricePrice
$2.890
Owned Owned
No

HOLD
CRH Medical Corp.(CRH-T) 

September 18, 2017

Had a tremendous run up to about $12, but got completely blindsided, and it pulled back heavily. Got stopped out around mid-$6. Thinks they are going to be okay long-term. There were some issues with insider selling at higher levels. If you own, continue to hold as it looks like it has bottomed.

biotechnology/pharmaceutical

Had a tremendous run up to about $12, but got completely blindsided, and it pulled back heavily. Got stopped out around mid-$6. Thinks they are going to be okay long-term. There were some issues with insider selling at higher levels. If you own, continue to hold as it looks like it has bottomed.

biotechnology/pharmaceutical
Jason Del Vicario

Portfolio Manager, HollisWealth...

PricePrice
$3.190
Owned Owned
No

DON'T BUY
CRH Medical Corp.(CRH-T) 

August 23, 2017

It had an amazing run this year.  It was a target of some short sellers, and then they missed on some earnings reports.  It is the worst for price momentum.  It is actually okay on valuation.  It has a decent balance sheet.  It is volatile and has poor price momentum.

biotechnology/pharmaceutical

It had an amazing run this year.  It was a target of some short sellers, and then they missed on some earnings reports.  It is the worst for price momentum.  It is actually okay on valuation.  It has a decent balance sheet.  It is volatile and has poor price momentum.

biotechnology/pharmaceutical
Jason Mann

CIO & Co-Founder, Edgehill Patners...

PricePrice
$3.050
Owned Owned
Unknown

WEAK BUY
CRH Medical Corp.(CRH-T) 

August 22, 2017

It fell apart and is now working itself back.  It got destroyed by credibility, short sellers came along and the stock has readjusted.  He thinks the worst is over.  It has earnings potential.

biotechnology/pharmaceutical

It fell apart and is now working itself back.  It got destroyed by credibility, short sellers came along and the stock has readjusted.  He thinks the worst is over.  It has earnings potential.

biotechnology/pharmaceutical
Peter Hodson

CEO & Head of Research, 5i Research Inc....

PricePrice
$3.120
Owned Owned
Yes

COMMENT
CRH Medical Corp.(CRH-T) 

August 15, 2017

A stock that is extremely popular with medical analysts. There has been a bit of a foul-up in performance and the stock has joined the Bear market. He doesn’t get the sense that it is as good as a lot of analysts seem to believe. You also have the setback of the Obama-care saga in the US.

biotechnology/pharmaceutical

A stock that is extremely popular with medical analysts. There has been a bit of a foul-up in performance and the stock has joined the Bear market. He doesn’t get the sense that it is as good as a lot of analysts seem to believe. You also have the setback of the Obama-care saga in the US.

biotechnology/pharmaceutical
Michael Smedley

Exec VP & Chief Investment Officer, Morgan Meighan & Ass...

PricePrice
$3.180
Owned Owned
No

COMMENT
CRH Medical Corp.(CRH-T) 

August 2, 2017

Provides anaesthesia services for gastro-intestinal procedures. They operate in the US, and Medicare and Medicaid are evaluating what people can bill for services. The company has said that the net impact will probably result in an 8% decline in revenue and a 16%-18% decline in EBITDA. When the news broke, the shares dropped about 50%-65%, so it is getting to a time where it has probably been a little oversold. This is going to be higher risk, so you need to be able to withstand 5% moves on any given day. They just did another acquisition and there is a hint that they will be doing many more.

biotechnology/pharmaceutical

Provides anaesthesia services for gastro-intestinal procedures. They operate in the US, and Medicare and Medicaid are evaluating what people can bill for services. The company has said that the net impact will probably result in an 8% decline in revenue and a 16%-18% decline in EBITDA. When the news broke, the shares dropped about 50%-65%, so it is getting to a time where it has probably been a little oversold. This is going to be higher risk, so you need to be able to withstand 5% moves on any given day. They just did another acquisition and there is a hint that they will be doing many more.

biotechnology/pharmaceutical
Ryan Modesto

Managing Partner, 5i Research...

PricePrice
$4.600
Owned Owned
Unknown

COMMENT
CRH Medical Corp.(CRH-T) 

July 26, 2017

This has been hit extremely hard. It trades to a pretty significant multiple and probably got ahead of itself. On the news and speculation that some kind of reimbursement was going to come, the stock sold down. The code changes are not being reimbursed to the same degree. In the past, they’ve been able to use their currency to a certain degree to make acquisitions. They have just secured a bigger line, so it looks like they’ve shored up their business fairly well. Fairly good cash flow. The reimbursement is going to hurt them, and then the private pay insurance, the majority of their business, will end up coming down over time as well. They are going to have to replace the lost revenue with increased business, either organically or by acquisition.

biotechnology/pharmaceutical

This has been hit extremely hard. It trades to a pretty significant multiple and probably got ahead of itself. On the news and speculation that some kind of reimbursement was going to come, the stock sold down. The code changes are not being reimbursed to the same degree. In the past, they’ve been able to use their currency to a certain degree to make acquisitions. They have just secured a bigger line, so it looks like they’ve shored up their business fairly well. Fairly good cash flow. The reimbursement is going to hurt them, and then the private pay insurance, the majority of their business, will end up coming down over time as well. They are going to have to replace the lost revenue with increased business, either organically or by acquisition.

biotechnology/pharmaceutical
Bruce Campbell (2)

President & Portfolio Manager, Stone Castle Investm...

PricePrice
$4.260
Owned Owned
Unknown

Showing 1 to 15 of 83 entries
<< < 1 2 3 4 5 > >>

No Comments.


You must be logged in to comment.

Successfully Saved Company